Trial Profile
Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Apr 2020 Status changed from active, no longer recruiting to completed.
- 05 Nov 2019 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 05 Nov 2019 Status changed from completed to active, no longer recruiting.